Evofosfamide, a new horizon in the treatment of pancreatic cancer

Anti-Cancer Drugs

Volumn 27, Issue 8, 2016, Pages 723-725

  Pourmorteza, Mohsen ^a   Rahman, Zia U ^a   Young, Mark ^a  

^a East Tennessee State University   (United States)

Author keywords

evofosfamide; pancreatic cancer; targeted chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; ERLOTINIB; EVOFOSFAMIDE; FLUOROURACIL; GEMCITABINE; PACLITAXEL; PRODRUG; NITROIMIDAZOLE DERIVATIVE; PHOSPHORAMIDE MUSTARD;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DNA ALKYLATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SELECTIVITY; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HUMAN; HYPOXIA; LOW DRUG DOSE; MELANOMA; MOLECULARLY TARGETED THERAPY; MUCOSAL DISEASE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN TOXICITY; STOMATITIS; SURVIVAL RATE; PANCREAS TUMOR; PATHOLOGY; TUMOR HYPOXIA;

ANTINEOPLASTIC AGENTS; HUMANS; NITROIMIDAZOLES; PANCREATIC NEOPLASMS; PHOSPHORAMIDE MUSTARDS; PRODRUGS; TUMOR HYPOXIA;

EID: 84970028175     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000386     Document Type: Review

References (34)

1. Koong AC, Mehta VK, Le QT, Fisher GA, Terris DJ, Brown JM, et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 2000; 48:919-922.
2. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26:225-239.
3. Semenza GL. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol 2014; 9:47-71.
4. Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2012; 12:9-22.
5. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2:38-47.
6. Luanpitpong S, Chanvorachote P, Nimmannit U, Leonard SS, Stehlik C, Wang L, Rojanasakul Y. Mitochondrial superoxide mediates doxorubicininduced keratinocyte apoptosis through oxidative modification of ERK and Bcl-2 ubiquitination. Biochem Pharmacol 2012; 83:1643-1654.
7. Yuan J, Glazer PM. Mutagenesis induced by the tumor microenvironment. Mutat Res 1998; 400:439-446.
8. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3:347-361.
9. Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res 2011; 17:2997-3004.
10. Hay MP, Hicks KO, Pruijn FB, Pchalek K, Siim BG, Wilson WR, Denny WA. Pharmacokinetic/pharmacodynamic model-guided identification of hypoxiaselective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport. J Med Chem 2007; 50:6392-6404.
11. Duan JX, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L, et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem 2008; 51:2412-2420.
12. Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, et al. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res 2012; 18:758-770.
13. Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, et al. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 2005; 65:3643-3655.
14. Grau C, Overgaard J. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother Oncol 1988; 13:301-309.
15. Kim IH, Brown JM. Reoxygenation and rehypoxiation in the SCCVII mouse tumor. Int J Radiat Oncol Biol Phys 1994; 29:493-497.
16. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66:7-30.
17. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-2413.
18. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-1966.
19. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369:1691-1703.
20. Borad MJ, Reddy S, Uronis H, Sigal DS, Cohn AL, Schelman WR, et al. Abstract LB-121: randomized phase II study of the efficacy and safety of gemcitabine+ TH-302 (G+ T) vs gemcitabine (G) alone in previously untreated patients with advanced pancreatic cancer. Cancer Res 2012;72(Suppl 8):LB-121.
21. Clinicaltrials.gov (2015). Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma - Full Text View - ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/study/NCT01746979. [Accessed 11 December 2015].
22. Sun JD, Liu Q, Ahluwalia D, Li W, Meng F, Wang Y, et al. Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer. Cancer Biol Ther 2015; 16:438-449.
23. DiGiulio S. FDA's fast track designation to evofosfamide for advanced pancreatic cancer. Oncol Times 2015. [Epub ahead of print].
24. Sun JD, Meng F, Liu Q, Ahluwalia D, Li W, Wang Y, et al. Association between Chk1 inhibitor AZD7762-mediated modulation of pharmacodynamic biomarkers and potentiation of hypoxia-activated prodrug TH-302 antitumor efficacy in a human tumor xenograft model. Cancer Res 2015; 75 (Suppl 15):S2424-S2424.
25. McWhirter E, Hamid O, Chmielowski B, Carvajal RD, Jaffray DA, Driscoll B, et al. A phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma. ASCO Annual Meeting Proceedings; 29 May to 2 June 2015; Chicago, Illinois.
26. Sun JD, Ahluwalia D, Liu Q, Li W, Wang Y, Meng F, et al. Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models. Am J Cancer Res 2015; 5:2139-2155.
27. Goldman J, Belani C, Novello S, von Pawel J, Csoszi T, Orlov S, et al. 142tiprandomized, double-blind, placebo-controlled trial of evofosfamide (th-302) in combination with pemetrexed in advanced non-squamous non-small cell lung cancer. Ann Oncol 2015; 26 (Suppl 1):i44-i44.
28. Garrido-Laguna Ig, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol 2015; 12:319-334.
29. Aprile G, Rihawi K, De Carlo E, Sonis ST. Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: a critical update. World J Gastroenterol 2015; 21:11793-11803.
30. Karakashev SV, Reginato MJ. Progress toward overcoming hypoxia-induced resistance to solid tumor therapy. Cancer Manag Res 2015; 7:253-264.
31. Tripathy D, Demetri GD. Evolving management options for soft-tissue sarcomas. Am J Hematol Oncol 2015; 11:30-35.
32. Zhang L, Marrano P, Wu B, Kumar S, Thorner PS, Baruchel S. Combined antitumor therapy with metronomic topotecan and hypoxia-activated prodrug, evofosfamide, in neuroblastoma and rhabdomyosarcoma preclinical models. Clin Cancer Res 2015. [Epub ahead of print].
33. Dhani NC, Serra S, Pintilie M, Schwock J, Xu J, Gallinger S, et al. Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole. Br J Cancer 2015; 113:864-871.
34. 18F-FAZA) uptake. J Nucl Med 2016; 57:361-366.